白细胞介素-33抗体治疗呼吸道合胞病毒诱导小鼠哮喘的效果观察

doi:10.3969/j.issn.1673-6184.2021.01.001

Abstract
Figure/Table
References (0)
Related Citation (3)

Download: PDF (9382 KB) HTML ()
Export: BibTeX | EndNote (RIS)

Abstract To study the role of interleukin-33 (IL-33) in acute exacerbation of allergic asthma induced by respiratory syncytial virus (RSV). Female BALB/c mice aged 3 weeks were randomly divided into five groups: PBS control; RSV infection; asthma mice model (sensitized and challenged by 1% ovalbumin); asthma model with RSV infection and treated with control antibody; asthma model with RSV infection and treated with anti-IL-33 antibody. Lung specimens were collected. The Lung sections were stained by hematoxylin-eosin to observe the changes of lung inflammation. il-13, il-4, rorγt, foxp3, ifnγ and il-33 mRNA expressions in the lung tissue were determined by real-time PCR. IL-13、IL-4、IL-33、IFN-γ and IL-17 level in bronchoalveolar lavage fluid(BALF) were measured by ELISA. Histological examination of lung tissue demonstrated that anti-IL-33 significantly inhibited allergen-induced lung inflammation. Both mRNA and protein level of IL-33 and IL-4 were significantly increased in the RSV asthma group. Treatment with anti-IL-33 significantly reduced the concentrations of IL-4, IL-13 and IL-17 compared with administration of a control antibody. The mRNA expression of il-13, il-4, rorγt, and foxp3 were also decreased. There was no change with IFN-γ expression. Our results demonstrated that anti-IL-33 antibodies can prevent the development of asthma in a mouse model, and blockade of IL-33 could be a new therapeutic strategy for acute exacerbation of allergic asthma.

Key words： Interleukin-33 Respiratory syncytial virus Asthma Helper T cells

Received: 04 February 2020 Published: 25 February 2021

ZTFEL:

R563.1

Corresponding Authors: JIE Zhijun

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FENG Jingjing
	CHEN Jiajun
	SHI Tianyun
	HE Yanchao
	JIE Zhijun

Cite this article:

FENG Jingjing,CHEN Jiajun,SHI Tianyun等. Anti-interleukin-33 treatment limits acute exacerbation induced by respiratory syncytial virus[J]. JOURNAL OF MICROBES AND INFECTIONS, 2021, 16(1): 2-9.

URL:

http://jmi.fudan.edu.cn/EN/10.3969/j.issn.1673-6184.2021.01.001 OR http://jmi.fudan.edu.cn/EN/Y2021/V16/I1/2

[1]	Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM.Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life[J].Thorax, 2010, 65:1045-1052.
[2]	Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA.IL-33,an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity, 2005, 23:479-490.
[3]	Licona-Limón P, Kim LK, Palm NW and Flavell RA.TH2,allergy and group 2 innate lymphoid cells[J].Nat. Immunol, 2013, 14:536-542.
[4]	Mirchandani, A，S.RJ. Salmond,and Liew F. Y.. Interleukin-33 and the function of innate lymphoid cells[J].Trends Immunol, 2012, 33:389-396.
[5]	Liu Q, Turnquist H.RImplications for interleukin-33 in solid organ transplantation[J].Cytokine, 2013, 62:183-194.
[6]	Kim YH, Yang TY, Park CS, Ahn SH, Son BK, Kim JH, Lim DH, Jang TY.Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis[J].Allergy, 2012, 67:183-90.
[7]	Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T.Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma[J].Biochem Biophys Res Commun, 2009, 386:181-185.
[8]	Jurak LM, Xi Y, Landgraf M, Carroll ML, Murray L, Upham JW.Interleukin 33 Selectively Augments Rhinovirus-Induced Type 2 Immune Responses in Asthmatic but not Healthy People [J].Front Immunol, 2018, 9:1895-undefined.
[9]	陈家君#，冯净净#，施天昀，陈鸿军，揭志军.在呼吸道合胞病毒感染导致哮喘急性发作中的作用[J].复旦学报医学版, 2020, 47:70-77.
[10]	Cayrol C, Duval A, Schmitt P, Roga S, Camus M, Stella A, Burlet-Schiltz O, Gonzalez-de-Peredo A, Girard JP.Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33[J].Nat Immunol., 2018, 19:375-385.
[11]	Rhiannon B，Werder, Vivian Zhang, Jason P.Lynch,Natale Snape,John WUpham,c,d Kirsten Spann,and Simon Phipps. .Chronic IL-33 expression predisposes to virus induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity[J].J Allergy Clin Immunol, 2018, 141:1607-1619.
[12]	Zeng S, Wu J, Liu J, Qi F, Liu B.IL-33 Receptor (ST2) Signalling is Important for Regulation of Th2-Mediated Airway Inflammation in a Murine Model of Acute Respiratory Syncytial Virus Infection[J].Scand J Immunol, 2015, 81:494-501.
[13]	Le Goffic R, Arshad MI, Rauch M, L'Helgoualc'h A, Delmas B, Piquet-Pellorce C, Samson M.Infection with influenza virus induces IL-33 in murine lungs[J].Am J Respir Cell Mol Biol, 2011, 45:1125-1132.
[14]	Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D.Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12[J].Immunobiology, 2016, 221:412-417.
[15]	Schiering C, Krausgruber T, Chomka A, Fr?hlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, Harrison OJ, Owens BMJ, L?hning M, Belkaid Y, Fallon PG, Powrie F.The alarmin IL-33 promotes regulatory T-cell function in the intestine[J].Nature, 2014, 513:564-568.
[16]	Alvarez F, Istomine R, Shourian M, Pavey N, Al-Aubodah TA, Qureshi S, Fritz JH, Piccirillo CA[J.The alarmins IL-1 and IL-33 differentially regulate the functional specialisation of Foxp3(+) regulatory T cells during mucosal inflammation[J].Mucosal Immunol, 2015, 12:746-760.
[17]	Cho K，A, Suh JW, Sohn JH, Park JW, Lee H, Kang JL, Woo SY, Cho YJ.IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice[J].Am J Physiol Lung Cell Mol Physiol, 2012, 302:429-440.
[18]	Park SH, Kim MS, Lim HX, Cho D, Kim TS.IL-33-matured dendritic cells promote Th17 cell responses via IL-1β and IL-6[J].Cytokine, 2017, 99:106-113.
[19]	Vocca L, Di Sano C, Uasuf CG, Sala A, Riccobono L, Gangemi S, Albano GD, Bonanno A, Gagliardo R, Profita M.IL-33ST2 axis controls Th2IL-31 and Th17 immune response in allergic airway diseases[J].Immunobiology., 2015, 220:954-963.
[20]	Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T.Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma[J].Biochem Biophys Res Commun, 2009, 386:181-185.